Introduction
============

In an era of increasing life expectancy, and with a growing population of survivors with various comorbidities, clinical decision making with regard to antithrombotic therapy for atrial fibrillation has become an even greater clinical challenge.[@ref1] Despite the well appreciated risk of stroke, oral anticoagulation is often not prescribed in older people, and undertreatment has been associated with adverse outcomes.[@ref2] [@ref3] However, physicians increasingly acknowledge that treatment decisions should probably be based on biological age rather than chronological age.[@ref4]

In various populations, polypharmacy has been associated with multiple comorbidities and frailty.[@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] Moreover, the risk of drug-drug interactions increases with the number of concomitant drug treatments. In addition, polypharmacy has been related to a higher risk of death and bleeding complications, also in patients with atrial fibrillation.[@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] In this context, patients with polypharmacy could have a differential response to anticoagulation therapy.

With the introduction of apixaban, a safer alternative to warfarin has become available that has also proven to be of value in patients considered unsuitable for warfarin treatment.[@ref18] [@ref19] In a previous report, we demonstrated that the benefits of apixaban versus warfarin were irrespective of age (\<65 years *v* 65-74 years *v* ≥75 years).[@ref20] However, among the elderly population, there are patients with hardly any comorbidity, whereas there are also younger patients with clinically significant comorbidity. On average, patients with atrial fibrillation use about four to six different drug treatments.[@ref10] [@ref11] [@ref21] Given that polypharmacy is generally defined as the use of five or more concomitant drug treatments, and thus represents an everyday issue, additional information on the effect of oral anticoagulation drugs in this subset of patients is of clinical importance.[@ref22] Especially in the case of apixaban, information on the effect of potentiating drugs is limited, and is of interest in patients treated with many concomitant drugs.

In this context, we performed a post hoc analysis of the ARISTOTLE trial (apixaban for reduction of stroke and other thromboembolic events in atrial fibrillation) to assess the association between the number of drugs used and the extent of comorbidity and adverse outcome.[@ref19] In addition, we looked at the relative treatment effect of apixaban versus warfarin in relation to the number of concomitant drug treatments.

Methods
=======

Patients
--------

The study design and main outcomes of the ARISTOTLE trial have been reported previously.[@ref19] [@ref23] In brief, ARISTOTLE was a multicentre, double blind, double dummy trial comparing apixaban with warfarin performed in 2006-11. Patients with documented atrial fibrillation or atrial flutter were eligible for inclusion if one or more of the following risk factors for thromboembolism were present: symptomatic heart failure within three months before inclusion or left ventricular function 40% or less; hypertension requiring pharmacological treatment; age 75 years or older; diabetes mellitus; and prior stroke, transient ischaemic attack, or systemic embolus.

Exclusion criteria included clinically significant mitral stenosis, conditions other than atrial fibrillation requiring anticoagulation, required aspirin treatment in a dose more than 165 mg/day or used in combination with a thienopyridine, recent ischaemic stroke, atrial fibrillation due to reversible causes, an increased bleeding risk considered to be a contraindication for oral anticoagulation, and severe renal insufficiency (that is, serum creatinine \>221.0 μmol/L or calculated creatinine clearance \<0.42 mL/s).

Patients were randomised to either 5 mg apixaban twice daily (n=9120) or a dose adjusted regimen of warfarin (n=9081). The target range for the international normalised ratio was 2.0 to 3.0, using a blinded encrypted point of care device. If two or more of the following criteria were present at baseline, patients received an apixaban dose of 2.5 mg twice daily or matching placebo: age 80 years or older, body weight up to 60 kg, serum creatinine 132.6 μmol/L or more. The study was approved by appropriate ethical committees at all sites and all patients provided written informed consent.

Concomitant drug treatments and comorbidity
-------------------------------------------

To investigate the association between the number of concomitant drugs and the extent of comorbidity, we assessed the number of drugs used for each patient. The study drug (apixaban or warfarin) and the matching placebo were counted as one drug. All treatments were categorised by drug class, according to the Anatomical Therapeutic Chemical classification system.[@ref24] Polypharmacy was defined as the use of five or more concomitant drugs.[@ref22]

The use of drugs known to interact with apixaban or warfarin was assessed for each patient. For apixaban, we studied drugs known to inhibit both the cytochrome P450 (CYP) 3A4 enzyme as well as the P-glycoprotein as depicted by the US Food and Drug Administration.[@ref25] For warfarin, we studied the use of drugs known to inhibit or potentiate its anticoagulant effect with a high probability according to the American College of Chest Physicians guideline.[@ref26]

All analyses performed were based on the baseline medication burden. Only for the anticoagulant we studied premature permanent discontinuation of the study drug; for patients assigned to warfarin, we calculated the time in therapeutic range according to the Rosendaal method.[@ref27]

Per protocol---the use of any concomitant drugs during the trial---was left to the discretion of the treating physician. The following concomitant drugs were prohibited in combination with the study drug: potent inhibitors of CYP3A4 (eg, azole antifungals, macrolide antibiotics, protease inhibitors, and nefazadone), aspirin taken as a daily dose of more than 165 mg, other anticoagulant agents (eg, unfractionated heparin, low molecular weight heparin, direct thrombin inhibitors, pentasaccharides), and glycoprotein IIb/IIIa inhibitors. If these agents were used during trial participation, the study drug was to be (temporarily) interrupted and restarted as soon as the prohibited drug was discontinued. During the trial, it was also advised to cautiously use aspirin in combination with a thienopyridine, chronic daily use of a non-steroid anti-inflammatory agent, and cytotoxic or myelosuppressive therapy.

Clinical outcomes
-----------------

We assessed outcomes in relation to the number of concomitant drug treatments used at the time of randomisation, during a median follow-up of 1.8 years (interquartile range 1.3-2.3 years). The primary efficacy outcome was stroke (that is, abrupt onset of focal neurological symptoms lasting at least 24 h) or a systemic embolism (that is, symptoms suggestive of an acute loss of blood flow to a non-cerebral artery, supported by evidence of embolism from surgical specimens, autopsy, angiography, or other objective testing). Key secondary efficacy outcomes included assessment of the type of stroke (ischaemic, haemorrhagic, or unspecified) and all cause death.

The primary safety endpoint was major bleeding according to the criteria set by the International Society on Thrombosis and Haemostasis, which includes any clinically overt bleeding event accompanied by one or more of the following: haemoglobin drop of 20 g/L or more over a 24 h period, transfusion of two or more units of packed red blood cells, bleeding at a critical site (that is, intracranial, intraspinal, intraocular, intra-articular, pericardial, intramuscular with compartment syndrome, or retroperitoneal), or fatal bleeding.[@ref28] Moreover, clinically relevant non-major bleeding events were monitored, and were defined as all clinically overt bleeding not meeting the criteria of major bleeding but leading to hospital admission, physician guided medical or surgical treatment, or a change in antithrombotic therapy. We defined the combined endpoint of net benefit as the combination of death, stroke, systemic embolism, and major bleeding.

Statistical analysis
--------------------

This post hoc analysis of ARISTOTLE was performed in 2015. Based on the tertiles of the distribution of the number of concomitant drugs used at baseline (that is, 0-5, 6-8, and ≥9 drugs), patients were classified in groups. Comorbidities, organised by organ system, were summarised for the three groups, as well as other baseline characteristics. A similar approach was followed for the different drug classes. Data were depicted as means and standard deviations for continuous variables and frequencies and percentages for categorical variables. We used one way analysis of variance and χ^2^ tests to compare groups. Efficacy, safety, and net benefit endpoints were compared among the three groups using rates per 100 patient years of follow-up and adjusted hazard ratios with 95% confidence intervals. Adjusted hazard ratios were derived using Cox regression models adjusting for sex and age and country of randomisation. In these models, age was considered non-linear and included as a restricted cubic spline. We assessed the randomised treatment effect within each group (0-5, 6-8, ≥9 drugs) using a Cox regression model to estimate hazard ratios for apixaban versus warfarin along with 95% confidence intervals. The homogeneity of the randomised treatment effect across groups was tested by adding interaction terms to the Cox regression model.

The proportional hazard assumption was evaluated using scaled Schoenfeld residuals and no clinically relevant departure from the assumption was observed. All the analyses were performed with SAS version 9.4 (SAS Institute).

Patient involvement
-------------------

No patients were involved in designing the study, in assessing the burden of the intervention on patients, or in explicitly setting outcome measures; however, outcomes were chosen to reflect daily practice described in earlier studies.[@ref29] Final study results of the ARISTOTLE trial were disseminated to study participants through their treating physicians.

Results
=======

Baseline characteristics and comorbidity
----------------------------------------

Table 1[](#tbl1){ref-type="table"} depicts baseline characteristics of the study population, categorised by groups of the number of drug treatments. The randomised treatment was well balanced across groups, and no relevant differences between apixaban and warfarin was observed for any of the drug categories across the population (supplementary table 1).

###### 

Baseline characteristics of ARISTOTLE trial participants, by number of concomitant drugs used

  Characteristic                                                                      No of drugs   P                           
  ----------------------------------------------------------------------------------- ------------- ------------- ------------- ---------
  Age (years, mean (SD))                                                              68 (10)       69 (10)       71 (9)        \<0.001
  Male                                                                                4687 (67.5)   4107 (63.2)   2991 (62.9)   \<0.001
  Weight (kg, mean (SD))                                                              81 (19)       84 (21)       89 (23)       \<0.001
  Body mass index (mean (SD))                                                         28.2 (5.4)    29.5 (6.0)    30.7 (6.5)    \<0.001
  Previous use of vitamin K antagonists \>30 days                                     3555 (51.2)   3656 (56.2)   3190 (67.1)   \<0.001
  Creatinine (mg/dL, mean (SD))                                                       1.02 (0.24)   1.06 (0.28)   1.12 (0.32)   \<0.001
  Region of enrolment                                                                                                           
   North America                                                                      736 (10.6)    1353 (20.8)   2385 (50.1)   \<0.001
   Latin America                                                                      1809 (26.1)   1306 (20.1)   353 (7.4)     
   Europe                                                                             3128 (45.1)   2811 (43.2)   1404 (29.5)   
   Asia                                                                               1270 (18.3)   1032 (15.9)   614 (12.9)    
  HAS-BLED score (mean (SD))                                                          1.45 (0.96)   1.77 (1.02)   2.25 (1.05)   \<0.001
  CHADS~2~ score (mean (SD))                                                          1.87 (1.02)   2.15 (1.08)   2.44 (1.17)   \<0.001
  CHADS~2~ score                                                                                                                
   ≤1                                                                                 3093 (44.5)   2057 (31.6)   1033 (21.7)   \<0.001
   2                                                                                  2309 (33.3)   2400 (36.9)   1807 (38.0)   
   ≥3                                                                                 1541 (22.2)   2045 (31.5)   1916 (40.3)   
  Randomised group                                                                                                              
   Apixaban                                                                           3424 (49.3)   3320 (51.1)   2376 (50.0)   0.13
   Warfarin                                                                           3519 (50.7)   3182 (48.9)   2380 (50.0)   
  Low dose apixaban/placebo received (2.5 mg twice daily)                             253 (3.6)     288 (4.4)     290 (6.1)     \<0.001
  Cardiovascular comorbidities                                                                                                  
   Coronary artery disease                                                            1795 (25.9)   2184 (33.6)   2063 (43.4)   \<0.001
   Prior myocardial infarction                                                        564 (8.1)     985 (15.2)    1036 (21.8)   \<0.001
   History of percutaneous coronary intervention or coronary artery bypass grafting   369 (5.3)     815 (12.5)    1292 (27.2)   \<0.001
   Congestive heart failure within 3 months                                           1931 (27.8)   2194 (33.7)   1416 (29.8)   \<0.001
   At least moderate valvular heart disease                                           926 (13.4)    1192 (18.3)   1116 (23.5)   \<0.001
   Syncope in past 5 years                                                            258 (3.7)     279 (4.3)     322 (6.8)     \<0.001
   Hypertension with pharmacological treatment                                        5844 (84.2)   5762 (88.6)   4310 (90.6)   \<0.001
   Peripheral artery disease                                                          193 (2.8)     290 (4.5)     401 (8.5)     \<0.001
   Aortic aneurysm                                                                    46 (0.7)      84 (1.3)      139 (3.0)     \<0.001
  Neurological/cerebrovascular comorbidities                                                                                    
  Carotid stenosis                                                                    54 (0.8)      93 (1.4)      190 (4.0)     \<0.001
  Transient ischaemic attack                                                          302 (4.4)     315 (4.8)     337 (7.1)     \<0.001
  Stroke                                                                              808 (11.6)    750 (11.5)    569 (12.0)    0.77
  Dementia                                                                            22 (0.4)      29 (0.5)      45 (1.0)      \<0.001
  Epilepsy                                                                            22 (0.4)      49 (0.8)      41 (0.9)      \<0.001
  Pulmonary comorbidities                                                                                                       
   Chronic obstructive pulmonary disease                                              435 (6.3)     626 (9.7)     889 (18.7)    \<0.001
   Asthma                                                                             157 (2.3)     250 (3.9)     462 (9.7)     \<0.001
   Sleep Apnoea                                                                       145 (2.1)     262 (4.0)     606 (12.8)    \<0.001
  Gastrointestinal comorbidities                                                                                                
   Dyspepsia                                                                          374 (5.4)     445 (6.9)     556 (11.7)    \<0.001
   Gastroesophageal reflux disease                                                    315 (4.5)     527 (8.1)     1074 (22.6)   \<0.001
   Peptic ulcer disease                                                               383 (5.5)     417 (6.4)     406 (8.5)     \<0.001
   Gastrointestinal surgery                                                           509 (7.3)     606 (9.3)     575 (12.1)    \<0.001
   Chronic liver disease                                                              190 (2.7)     193 (3.0)     121 (2.5)     0.39
  Endocrine comorbidities                                                                                                       
      Hypothyroidism or hyperthyroidism                                               429 (6.2)     733 (11.3)    878 (18.5)    \<0.001
      Diabetes mellitus                                                               806 (11.6)    1603 (24.7)   2138 (45.0)   \<0.001
      End organ damage due to diabetes mellitus                                       75 (1.1)      219 (3.4)     459 (9.7)     \<0.001
  Musculoskeletal comorbidities                                                                                                 
      Falls within 1 year                                                             140 (2.3)     215 (3.6)     398 (8.8)     \<0.001
      Previous non-traumatic fracture                                                 299 (4.3)     339 (5.2)     436 (9.2)     \<0.001
      Osteoporosis                                                                    151 (2.2)     298 (4.6)     521 (11.0)    \<0.001
  Renal comorbidities                                                                                                           
      Chronic kidney disease                                                          434 (6.3)     520 (8.0)     553 (11.6)    \<0.001
      Creatine clearance \<50 mL/min                                                  927 (13.4)    1112 (17.2)   970 (20.5)    \<0.001
  Haematological comorbidities                                                                                                  
      History of Anemia                                                               210 (3.0)     359 (5.5)     676 (14.2)    \<0.001
      Thrombocytopenia (platelet at baseline \<150×10^9^/L)                           510 (7.6)     467 (7.4)     332 (7.2)     0.77
      Bleeding history                                                                779 (11.2)    1029 (15.8)   1232 (25.9)   \<0.001
  No of organ systems affected (median (IQR))                                         2, 1-3        2, 2-3        3, 2-4        \<0.001

Data are no (%) of patients unless stated otherwise. Subcategorisation of all baseline characteristics per treatment allocation is presented in web table 1. CHADS~2~=congestive heart failure, hypertension, age (≥75 years), diabetes mellitus, and previous stroke/transient ischaemic attack/systemic embolism (doubled risk weight); HAS-BLED=uncontrolled hypertension, abnormal renal and liver function, prior stroke, bleeding history (or predisposition), labile international normalised ratio, age\>65 years, drugs predisposing to bleed, and alcohol use disorders; IQR=interquartile range; SD=standard deviation.

Patients using more drug treatments were older, more often female, and less often warfarin naive at study entry (table 1[](#tbl1){ref-type="table"}). The CHADS~2~ and HAS-BLED scores increased with the increasing number of concomitant drug treatments. With the increasing number of drugs, the associated comorbidity increased significantly (table 1[](#tbl1){ref-type="table"}).

Concomitant drugs---classification according to organ or system
---------------------------------------------------------------

The median number of drug treatments used was six (interquartile range 5-9) and polypharmacy was present in 13 932 (76.5%) patients (supplementary fig 1). Among the 18 201 ARISTOTLE participants, we saw marked regional differences in the number of drugs used: 53% (2385/4474) of patients enrolled in North America used nine or more drugs (United States 1980/3417 (58%); Canada 405/1057 (38%)), compared with 10-21% for the other regions (table 1[](#tbl1){ref-type="table"}). Although there were more patients with comorbidity in four or more organ systems in the USA than in non-US countries (1389 (43.3%) *v* 2602 (20.5%)), we observed a greater number of drugs used in the USA regardless of the number of comorbidities.

Across groups of increasing number of drugs, the median number of represented drug classes increased from two (interquartile range two to three) to five (four to five), for patients using up to five drugs and for those using nine or more drugs, respectively.

###### 

Distribution of drug classes used by ARISTOTLE trial participants, by number of concomitant drugs used

  Drug class                                                              No of drugs   P                           
  ----------------------------------------------------------------------- ------------- ------------- ------------- ---------
  Alimentary tract and metabolism                                         962 (13.9)    3045 (46.8)   4094 (86.1)   \<0.001
  Blood and blood forming organs (excluding apixaban/warfarin)            2282 (32.9)   4322 (66.5)   4116 (86.5)   \<0.001
  Cardiovascular system                                                   6460 (93.0)   6468 (99.5)   4737 (99.6)   \<0.001
  Dermatological drugs                                                    34 (0.5)      96 (1.5)      346 (7.3)     \<0.001
  Genitourinary system and sex hormones                                   173 (2.5)     510 (7.8)     936 (19.7)    \<0.001
  Systemic hormonal preparations, excluding sex hormones and insulins     181 (2.6)     508 (7.8)     852 (17.9)    \<0.001
  Anti-infective drugs for systemic use                                   44 (0.6)      161 (2.5)     347 (7.3)     \<0.001
  Antineoplastic and immunomodulating agents                              14 (0.2)      60 (0.9)      152 (3.2)     \<0.001
  Musculoskeletal system                                                  202 (2.9)     688 (10.6)    1350 (28.4)   \<0.001
  Nervous system                                                          523 (7.5)     1448 (22.3)   2376 (50.0)   \<0.001
  Antiparasitic products, insecticides, and repellents                    0 (0.0)       13 (0.2)      46 (1.0)      \<0.001
  Respiratory system                                                      164 (2.4)     600 (9.2)     1336 (28.1)   \<0.001
  Sensory organs                                                          41 (0.6)      115 (1.8)     300 (6.3)     \<0.001
  Various                                                                 126 (1.8)     247 (3.8)     630 (13.2)    \<0.001
  Interacting drugs                                                                                                 
   ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inhibitor   1128 (16.2)   1431 (22.0)   1301 (27.4)   \<0.001
   ≥1 combined P-glycoprotein and weak-moderate-strong CYP3A4 inducer     12 (0.2)      34 (0.5)      47 (1.0)      \<0.001
   ≥1 highly probable VKA inhibiting drug                                 8 (0.1)       19 (0.3)      33 (0.7)      \<0.001
   ≥1 highly probable VKA potentiating drug                               973 (14.0)    1406 (21.6)   1387 (29.2)   \<0.001
   Use of acetylsalicylic acid, NSAIDs, or prednisone                     956 (13.8)    2064 (31.7)   2362 (49.7)   \<0.001

Data are no (%) of patients. CYP=cytochrome P450; VKA=vitamin K antagonist, NSAIDs=non-steroidal anti-inflammatory drugs.

Across the three study groups, there were no relevant differences between apixaban and warfarin regarding the proportion of patients in each of the defined drug classes. For each of the respective drug classes, the proportion of patients increased statistically significantly from the group using up to five concomitant drugs to the group using nine or more concomitant drugs. Across groups of increasing concomitant medication, the proportion of patients in the respective drug classes was higher in the USA than in non-US countries (supplementary table 2A and 2B). Despite this difference in prescription pattern, we saw a clear association between the number of concomitant drugs used at baseline and the number of comorbidities, both for the US and non-US populations.

Clinical outcomes according to the number of concomitant drugs
--------------------------------------------------------------

### Efficacy outcomes

With regard to the primary efficacy endpoint (stroke and systemic embolism), patients using more concomitant drugs were at higher risk, with an increase in event rates from 1.29 per 100 patient years for patients using up to five drugs to 1.57 per 100 patient years for patients using nine or more drugs (P\<0.001; table 3[](#tbl3){ref-type="table"}). For the secondary efficacy outcomes, there was also a significant association with the number of concomitant drugs. We saw a twofold increased risk for all cause death for patients using nine concomitant drugs or more compared with those using up to five concomitant drugs (P\<0.001).

###### 

Efficacy and safety outcomes by number of concomitant drug treatments used by ARISTOTLE trial participants

  Event                                      0-5 drugs                  6-8 drugs                  ≥9 drugs                 P                                           
  ------------------------------------------ -------------- ----------- ----------- -------------- ------------------------ --- -------------- ------------------------ ---------
  **Efficacy outcomes**                                                                                                                                                 
  Stroke/SE                                  1.29 (166)     Reference               1.48 (176)     1.270 (1.022 to 1.577)       1.57 (135)     1.539 (1.190 to 1.991)   0.004
  Ischaemic or uncertain type of stroke      0.82 (106)     Reference               1.11 (132)     1.475 (1.136 to 1.915)       1.15 (99)      1.738 (1.275 to 2.369)   0.001
  All cause death                            3.01 (396)     Reference               3.80 (462)     1.409 (1.229 to 1.616)       4.70 (414)     2.031 (1.735 to 2.377)   \<0.001
  **Safety outcomes**                                                                                                                                                   
  Major bleeding                             1.91 (224)     Reference               2.46 (267)     1.243 (1.036 to 1.491)       3.88 (298)     1.721 (1.414 to 2.095)   \<0.001
  Intracranial                               0.54 (64)      Reference               0.55 (61)      1.025 (0.722 to 1.456)       0.62 (49)      1.153 (0.795 to 1.673)   0.73
  Gastrointestinal                           0.47 (56)      Reference               0.71 (78)      1.498 (1.062 to 2.111)       1.15 (90)      2.429 (1.740 to 3.391)   \<0.001
  Clinically relevant non-major bleeding     2.09 (243)     Reference               2.47 (267)     1.183 (0.994 to 1.408)       3.30 (252)     1.574 (1.319 to 1.877)   \<0.001
  Any bleeding                               17.41 (1742)   Reference               21.40 (1908)   1.167 (1.092 to 1.247)       29.63 (1766)   1.452 (1.348 to 1.565)   \<0.001
  **Net benefit outcomes**                                                                                                                                              
  Stroke/SE/major bleeding/all cause death   5.24 (665)     Reference               6.59 (769)     1.320 (1.187 to 1.468)       8.92 (743)     1.838 (1.631 to 2.071)   \<0.001
  **Other outcomes**                                                                                                                                                    
  Permanent study drug discontinuation       14.32 (1699)   Reference               14.99 (1655)   1.053 (0.982 to 1.129)       17.44 (1372)   1.218 (1.123 to 1.322)   \<0.001
  Time in therapeutic range \<66%^\*^        53.2 (1823)    Reference               50.2 (1564)    0.887 (0.805 to 0.977)       44.9 (1044)    0.716 (0.644 to 0.795)   \<0.001

Hazard ratios and P values adjusted by country (strata), sex, and age (spline). SE=systemic embolism.

\*Values reported are percentage (number of patients) and unadjusted odd ratios for patients randomised to warfarin.

### Safety outcomes

The risk of major bleeding for patients using six or more concomitant drugs was significantly higher than for those using up to five drugs (using 0-5 drugs as reference group; 6-8 drugs: adjusted hazard ratio 1.24 (95% confidence interval 1.04 to 1.49); ≥9 drugs: 1.72 (1.41 to 2.10); table 3[](#tbl3){ref-type="table"}). When subdividing major bleeding according to the location, we observed no significant difference across groups for intracranial bleeding (P=0.73), while the event rate for gastrointestinal bleeding significantly increased with a higher number of concomitant drugs*.*

### Net benefit outcome

With regard to the combined endpoint of stroke, systemic embolism, major bleeding, and all cause death, event rates increased across groups (5.24, 6.59, and 8.92 per 100 patient years for 0-5, 6-8, and ≥9 drugs, respectively, P\<0.001; table 3[](#tbl3){ref-type="table"}). This increase was associated with an adjusted hazard ratio of 1.84 (95% confidence interval 1.63 to 2.07) for patients using at least nine concomitant drugs compared with those using up to five concomitant drugs (table 3[](#tbl3){ref-type="table"}).

### Other outcomes

With the use of increasing numbers of concomitant drugs, the risk of permanent discontinuation of study drug rose significantly (discontinuation rates 14.3, 15.0, and 17.4 per 100 patient years at risk for 0-5, 6-8, and ≥9 drugs, respectively, P\<0.001; table 3[](#tbl3){ref-type="table"}). Poor control of the international normalised ratio during follow-up (that is, time in therapeutic range \<66%) was highest in the patients using up to five concomitant drugs and decreased across the groups (53.2%, 50.2%, and 44.9% for 0-5, 6-8, and ≥9 drugs, respectively, P\<0.001; table 3[](#tbl3){ref-type="table"}).

Treatment effect
----------------

Figures 1 and 2[](#f1 f2){ref-type="fig"} outline the treatment effect of apixaban versus warfarin for the different study outcomes, categorised by the number of concomitant drugs used at baseline.

![**Fig 1** Association between randomised treatment and main outcomes, by number of concomitant drugs used at baseline by ARISTOTLE trial participants](focj031222.f1_default){#f1}

![**Fig 2** Treatment comparisons for efficacy, safety, and net benefit outcomes between apixaban and warfarin according to the number of concomitant drugs used by ARISTOTLE trial participants at baseline](focj031222.f2_default){#f2}

For the primary efficacy outcome, risk reductions of apixaban versus warfarin were consistent, irrespective of the number of concomitant drugs used (P~interaction~=0.82), with lower event rates on apixaban for all groups. Also for the secondary efficacy outcomes, no significant interactions were observed.

With regard to major bleeding, relative risk reductions for apixaban versus warfarin fell with increasing number of concomitant drugs (P~interaction~=0.017), corresponding to absolute rate reductions per 100 patient years of 1.28, 0.82, and 0.66 for the three groups (0-5, 6-8, and ≥9 drugs, respectively). For intracranial bleeding, the absolute benefit on apixaban showed a numerical increase across the groups, by contrast with the numerical differences in major gastrointestinal bleeding observed between treatment groups. With regards to the combined outcome of stroke, systemic embolism, major bleeding, and all cause death, we observed no significant interaction between treatment groups (P=0.10). Rates of permanent study drug discontinuation were lower for apixaban in all groups (P~interaction~=0.36).

Interacting drugs
-----------------

The proportion of patients using an interacting drug increased across the groups of concomitant drug treatments, both for CYP3A4 and P-glycoprotein inhibitors as warfarin potentiating drugs. At least one combined inhibitor of both the CYP3A4 enzyme and P-glycoprotein was used by 20.9% (1903/9120) of patients treated with apixaban, and 21.1% (1913/9081) of patients treated with warfarin used vitamin K antagonist potentiating drugs. For the concomitant use of aspirin, non-steroidal anti-inflammatory drugs, or prednisone, proportions were 13.8%, 31.7%, and 49.7% for the three groups (0-5, 6-8, and ≥9 drugs, respectively; P\<0.001).

Rates of major bleeding did not significantly differ between patients with or without combined CYP3A4 and P-glycoprotein inhibitors (2.59 *v* 2.61 per 100 patient years, respectively). Moreover, no significant interaction with the treatment allocation was observed (P=0.39; table 4[](#tbl4){ref-type="table"}). With regard to drugs known to potentiate warfarin, we also observed no difference in the event rate of major bleeding for users versus non-users (2.60 *v* 2.61 per 100 patient years).

###### 

Major bleeding rates with apixaban or warfarin according to use of interacting drugs by ARISTOTLE trial participants

  Interacting drugs                                                       Use of potentiating drug (rate per 100 patient years (no of patients))               No use of potentiating drug (rate per 100 patient years (no of patients))   P~interaction~                
  ----------------------------------------------------------------------- ------------------------------------------------------------------------ ----------- --------------------------------------------------------------------------- ---------------- ------------ ------
  ≥ 1 combined P-glycoprotein and weak/moderate/strong CYP3A4 inhibitor   2.27 (72)                                                                2.91 (93)                                                                               2.10 (255)       3.14 (369)   0.39
  ≥1 highly probable VKA potentiating drug                                2.03 (62)                                                                3.16 (96)                                                                               2.16 (265)       3.07 (366)   0.64

CYP=cytochrome P450; VKA=vitamin K antagonist.

Discussion
==========

In this post hoc analysis of the ARISTOTLE trial, we observed that polypharmacy was present in three quarters of patients and that the number of concomitant drug treatments is associated with increased comorbidity. Prescription patterns differed across regions, with about twice the number of concomitant drugs used in the USA versus non-US countries. Adverse clinical outcomes occurred more frequently in patients treated with a higher number of concomitant drugs. The benefits of apixaban in reducing stroke were preserved, regardless of the number of concomitant drugs taken. In terms of safety, although rates of major bleeding were consistently lower with apixaban than with warfarin, the magnitude of benefit with apixaban decreased with the increasing number of concomitant drug treatments.

Polypharmacy and adverse outcomes
---------------------------------

Atrial fibrillation affects older patients, who have a varying extent of comorbidity and associated concomitant drug treatments.[@ref30] Previous studies have reported rates of polypharmacy in 40-64% of patients with atrial fibrillation, with varying prescription patterns and inclusion and exclusion criteria.[@ref9] [@ref10]

Various reports have demonstrated, for different clinical conditions, that polypharmacy is associated with increased comorbidity.[@ref5] [@ref6] [@ref7] [@ref8] [@ref9] [@ref10] In addition, studies focusing on older populations have linked polypharmacy to adverse drug reactions, falls, disability, and frailty.[@ref6] [@ref7] [@ref8] In this context, patients with polypharmacy could constitute a population with a differential response to oral anticoagulation.

Although differences in prescription thresholds could affect the classification of patients in individual cases, several reports have repeatedly demonstrated on a group level that polypharmacy is associated with comorbidity and adverse outcome, also in populations with atrial fibrillation.[@ref6] [@ref7] [@ref8] [@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] [@ref16] [@ref17] Our findings of higher risks of bleeding, stroke, and all cause mortality with increasing numbers of drugs are in line with these previous observations.

Notably, this increased risk of adverse outcomes should be placed in the context of the association between the number of drug treatments and comorbidities present at baseline, indicating a more frail status of patients with polypharmacy. If we were to adjust for these baseline differences, it is likely that the risk of adverse outcomes related to the number of drugs would diminish. However, we did not study the association between polypharmacy and adverse outcomes independent of the baseline difference. On the contrary, we studied the number of concomitant drugs as a marker of comorbidity or frailty, and adverse outcome.

As such, we performed adjustments limited to age, sex, and country of randomisation. It was important to adjust for region, given the differences in prescription patterns between countries that are independent of differences in comorbidity. It is striking that the USA had more use of polypharmacy than non-US countries, which was not solely explained by comorbidity.

Polypharmacy and treatment effect
---------------------------------

Considering that patients with polypharmacy have a higher risk of adverse outcomes and multiple coexisting impairments, it is of special interest to study whether the main trial results of the ARISTOTLE study are consistent among patients using many concomitant drug treatments. For the primary endpoint of stroke and systemic embolism, we saw an absolute risk reduction from 1.60% per year with warfarin to 1.27% per year with apixaban (21% relative risk reduction in the complete population, which was consistent irrespective of the number of concomitant drugs used).[@ref19]

Overall, the use of apixaban was associated with an absolute risk reduction in major bleeding from 3.09% to 2.13% per year when compared with warfarin (relative risk reduction 31%).[@ref19] However, we observed a significant treatment interaction with relative risk reductions of apixaban varying from 50% (0-5 drugs) to 28% (6-8 drugs) and 16% (≥9 drugs), respectively. Importantly, the risk reduction of intracranial bleeding did not diminish with an increasing number of concomitant drugs. Therefore, the fact that the relative benefit of apixaban over warfarin appears to diminish across groups is due to other types of major bleeding. For example, with increasing numbers of drug treatments, the numerical difference in gastrointestinal bleeding events shifts from a benefit for apixaban (0-5 drugs) to no apparent difference (≥9 drugs) between both oral anticoagulants.

The ROCKET AF trial, with overall similar rates of major bleeding for rivaroxaban and warfarin, also showed a treatment interaction for major bleeding.[@ref10] The hazard ratio for major bleeding in patients using fewer concomitant drugs (0-4) was lower than that observed in the entire study population (adjusted hazard ratio 0.69 (95% confidence interval 0.51 to 0.94) *v* 1.04 (0.90 to 1.20)). For mortality, there was no difference in treatment effect of rivaroxaban in patients with polypharmacy. In the ARISTOTLE trial, apixaban reduced the risk of mortality from 3.94% to 3.52% per year when compared with warfarin in the main study---a relative risk reduction of 11% that was consistent regardless of the number of concomitant drug treatments.[@ref19]

In the ARISTOTLE trial as well as in the ROCKET AF trial, patients with polypharmacy were older.[@ref10] Nonetheless, the relative reduction of both apixaban and rivaroxaban on major bleeding proved to be consistent across the different age groups in previously reported post hoc analyses.[@ref20] [@ref31] Importantly, this implies that our findings cannot be inferred to older patients in general. In fact, our findings are irrespective of age and sex, and refer to the group of patients, both younger and older, with multiple comorbidities and drug treatments.

Possible explanations for the attenuation of the observed safety benefit of apixaban with increasing concomitant drugs include effects of comorbidity and drug-drug interactions, or the play of chance. We demonstrated that various coexisting diseases (chronic obstructive pulmonary disease, gastrointestinal disease, renal impairment) were more frequent with increasing numbers of concomitant drugs. Of interest, given the consistent risk reduction of apixaban for intracranial bleeding, the treatment interaction for major bleeding is related to other major bleeding. Risk factors for gastrointestinal bleeding complications (eg, previous gastric ulcers; gastrointestinal surgery; dyspepsia; use of aspirin, prednisone, or non-steroidal anti-inflammatory drugs) were more prevalent among patients with polypharmacy. Other non-gastrointestinal risk factors for bleeding were also more often common in patients using more concomitant drugs (eg, older age, renal impairment, anaemia, diabetes, and previous bleeding).[@ref32]

Other aspects that could account for the reduced benefit of apixaban in patients using nine concomitant drugs or more are the higher rates of permanent study drug discontinuation and lower proportion of patients who were vitamin K antagonist naive (supplementary table 1).[@ref33] The lower rates of patients on study medication may have blunted the observed risk reduction of apixaban in this group. In addition, bleeding rates on warfarin are usually lower in patients with prior experience vitamin K antagonists. Finally, the better control of international normalised ratio in the patients with more than nine concomitant drug treatments may have diminished bleeding rates on warfarin.[@ref34] [@ref35]

For drug-drug interactions, we specifically studied the effect of warfarin potentiating drugs and the combination of CYP3A4 and P-glycoprotein inhibitors, given the possibility of higher plasma concentrations of apixaban with these agents. However, we saw no evidence of differential treatment effect between apixaban and warfarin across groups of the number of concomitant drugs when accounting for warfarin or apixaban potentiating drugs.

The effects of non-vitamin K antagonist oral anticoagulants in patients with polypharmacy have also been studied in a pooled analysis of data, in the setting of secondary prevention after a venous thromboembolism.[@ref15] For major bleeding, there was no treatment interaction when comparing the safety of dabigatran versus warfarin in patients using three or fewer concomitant drugs with those using more than three concomitant drugs. However, these patients were much younger and less fragile than patients with atrial fibrillation.

With regards to symptomatic venous thromboembolism, the issue of a potential different response to oral anticoagulation therapy in patients considered to be fragile has been studied in more detail.[@ref36] In this study, patients were considered to be fragile if they were over 75 years old, had a low body weight (\<50 kg), or had impaired renal function (creatinine clearance \<0.83 mL/s). Although this certainly identifies patients at risk, incorporation of multiple comorbidities would allow for a more refined identification of frail patients within these specific subgroups.[@ref37]

In summary, polypharmacy could be a marker of multimorbidity and a predictor of adverse outcomes, and it might provide a first general impression of a patient's frailty. Future research on a differential response with oral anticoagulation therapy in patients with multimorbidity should focus on incorporation of the key frailty criteria. For example, the Fried criteria can help to identify higher risk patients who are often under-represented in clinical trials.[@ref38] This group may deserve additional attention, as far as the generalisability of trial data is concerned, not only in the field of anticoagulation therapy but also for other treatments.[@ref39]

Study limitations
-----------------

This study had several limitations. Firstly, it was a post hoc analysis, although there was a prospective, detailed analysis plan. Secondly, the analyses were based on the drug burden at baseline, without information on drug changes, reason, or appropriateness of drug prescription. However, with polypharmacy that is often driven by chronic medical conditions, substantial reductions in the number of drugs are not likely. Thirdly, as the number of drugs might not only be driven by the extent of comorbidity, but also by prescription patterns, we acknowledge that this might have affected classification on an individual level. However, on a group level, the use of polypharmacy has repeatedly demonstrated to be a marker of the extent of comorbidity and associated with adverse outcome.

The cut-off value of five or more drugs is arbitrary, although it has been used in many previous reports. Given that three quarters of patients would qualify for polypharmacy according to this definition, our statistical approach was not arbitrary, but based on a common approach of dividing our data into groups to explore polypharmacy across categories that are sufficiently large to avoid the hazard of small subgroups. With regard to generalisability, our findings might not apply to an unselected population with atrial fibrillation, given the selection that occurs when enrolling patients in clinical trials.

Conclusions
-----------

In this population with atrial fibrillation on oral anticoagulation therapy, polypharmacy (≥5 drugs) was observed in three quarters of patients. The extent of comorbidity increased with greater numbers of concomitant drugs, which was irrespective of regional prescription patterns. Mortality, stroke, and major bleeding were also more frequent with increasing numbers of drugs. As for a potential differential response to anticoagulation therapy in this context, we observed that apixaban was superior to warfarin in terms of efficacy, regardless of the number of drugs taken, whereas its magnitude of benefit on major bleeding decreased with higher numbers of concomitant drugs. Important differences in the comorbidity profile could account for this, and it did not appear that warfarin or apixaban potentiating drugs (CYP3A4, P-glycoprotein inhibitors) explained this observed treatment interaction. In summary, apixaban is more effective than and is at least as safe as warfarin in patients with atrial fibrillation, regardless of polypharmacy.

### What is already known on this topic

1.  Polypharmacy is associated with increased comorbidity, frailty, and drug-drug interactions, and has repeatedly been shown to be a marker of adverse clinical outcome; therefore, patients with polypharmacy could have a differential response to anticoagulation therapy

2.  For patients with atrial fibrillation, apixaban has been more effective and safer than warfarin, but whether this also holds true for patients using many concomitant drugs is unknown

### What this study adds

1.  For patients with atrial fibrillation, apixaban was more effective than warfarin regardless of the number of concomitant drugs used

2.  Although major bleeding rates were consistently lower with apixaban than with warfarin, the magnitude of benefit with apixaban seemed to decrease with the increasing number of concomitant drug treatments

3.  In this patient group, the specific use of warfarin or apixaban potentiating drugs did not seem to account for this differential response to anticoagulation therapy with regard to major bleeding
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